PDCD6IP and prostate cancer: There was a trend for lower expression of ALIX (PDCD6IP) to stratify patients with increased prostate cancer recurrence (P = 0.059), and reduced expression of Syntaxin 12 (STX12) was also indicative of at-risk patients, with significant stratification (P = 0.001; Figure 2).